Literature DB >> 22154361

Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.

Eli Peled1, Alexey Rovitsky, Elena Axelman, Doron Norman, Benjamin Brenner, Yona Nadir.   

Abstract

BACKGROUND: Orthopedic hip and knee surgeries are followed by a hypercoagulable state. Heparanase is implicated in inflammation, coagulation activation and angiogenesis. Recently, heparanase was shown to directly interact with tissue factor (TF) and to enhance the generation of factor Xa (Nadir et al., Haematologica, 2010). In addition, an assay assessing heparanase procoagulant activity has been lately developed (Nadir et al., Thromb Res, 2011). In the present study heparanase level and procoagulant activity in patients undergoing orthopedic surgery were assessed.
METHODS: The study group included 50 orthopedic patients. 31 patients underwent hip surgery and 19 had knee operation. 15 individuals suffered from traumatic hip fractures and 35 had osteoarthrosis of hip or knee joints. All patients received prophylactic dose of enoxaparin starting 6-8 hours post operation and lasting for 5 weeks. Plasma samples were drawn preoperatively and at 1 hour, 1 week and 1 month post operation. Samples were tested for heparanase levels by ELISA and TF/heparanase complex activity, TF activity, heparanase procoagulant activity, factor Xa and thrombin levels using chromogenic substrates.
RESULTS: Heparanase levels were significantly higher 1 hour and 1 week post operatively compared to preoperative levels (p<0.05, p<0.005, respectively). The most dramatic changes were observed in heparanase procoagulant activity reaching a 2 fold increase 1 week postoperatively and 1.7 fold increase 1month after surgery (p<0.0001, p<0.0001, respectively). Levels of factor Xa and thrombin did not significantly change.
CONCLUSIONS: Heparanase is involved in coagulation activation of orthopedic surgery patients. Heparanase procoagulant activity is highest 1 week postoperatively and remains high 1month after operation. Considering extending prophylactic anticoagulant therapy or evaluating heparanase procoagulant activity may potentially prevent late thrombotic events.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154361     DOI: 10.1016/j.thromres.2011.09.021

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  A rechargeable anti-thrombotic coating for blood-contacting devices.

Authors:  Hyun Ok Ham; Carolyn A Haller; Guowei Su; Erbin Dai; Madhukar S Patel; David R Liu; Jian Liu; Elliot L Chaikof
Journal:  Biomaterials       Date:  2021-07-09       Impact factor: 15.304

2.  Heparanase and coagulation-new insights.

Authors:  Yona Nadir
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

3.  Serum heparanase levels and left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.

Authors:  Mehmet Fatih Yilmaz; Emrah Acar; Mehmet Inanir; Can Yücel Karabay; Ibrahim Akin Izgi
Journal:  Herz       Date:  2021-08-05       Impact factor: 1.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.